Map the genetic landscape before your clinical trial

Atlas qDMS delivers high-resolution data for every resistance mutation: dose-aware intelligence to design smarter trials and de-risk your pipeline.

Schedule a 30-Minute Consult

90% of drug candidates fail after entering clinical studies

~50% of these failures are due to preventable efficacy gaps. Atlas qDMS is engineered to identify these liabilities in the lab (where they cost pennies) rather than in the clinic, where they cost programs.

We’re making it possible to predict drug efficacy early and accurately.

Atlas Biotech brings clarity to discovery by characterizing target liabilities, profiling safety windows, and engineering Custom Models to ensure biological relevance, so you can build pipelines with confidence and bring breakthrough therapies to market faster.

QDMS: Our Breakthrough Method

With state-of-the-art quantitative deep mutational scanning (qDMS), Atlas Biotech can reveal which mutations respond to or resist your drug by testing thousands of variants at once. Unlike traditional DMS, we directly measure dose-response in patient-relevant conditions, leveraging translational pharmacology for precise predictions.

1

Select Your Target Protein

We begin with your target protein of interest—whether it's a kinase, receptor, or any clinically relevant protein where understanding mutation effects is critical for drug development.

Works with any druggable protein target
Oncology, autoimmune, and infectious disease applications
Resistance profiling for existing therapeutics

2

Atlas Biotech Generates Variant Library

We generate a comprehensive DNA library encoding thousands of protein variants, systematically mutating each position to test every possible amino acid substitution in parallel.

Comprehensive saturation mutagenesis
All 20 amino acids at every position
Thousands of variants tested simultaneously

3

Get Quantitative Dose-Response Data

Unlike traditional DMS that ranks mutations relatively, qDMS measures actual IC50 values for each variant. The result: a complete resistance and sensitivity map under patient-relevant drug concentrations.

Actual IC50 measurements, not relative rankings
Patient-relevant drug concentrations
Complete resistance and sensitivity mapping

Secure the Whole Program

Cell Line Generation

BIOLOGICALLY TRUE DATA

Standard cell lines often yield standard failures. We engineer custom, patient-relevant cell models (Custom Lines) so your qDMS efficacy data reflects biological reality, not just a lab artifact.
Specificity Screenings

THE SAFEGUARD

Efficacy means nothing if toxicity kills the program. While qDMS confirms the hit, our Specificity Screening (TELTALE) confirms the safety, predicting adverse events before they reach the clinic.
Functional Genomics

DURABLE THERAPIES

Pairing qDMS resistance maps with our Functional Genomics (Bypass) screens reveals how tumors rewire to survive: helping you design durable therapies that result in successful clinical trials.